Diurnal Group plc (DNL) Ordinary 5p
Diurnal Group plc is a United Kingdom-based specialty pharmaceutical company. The Company is focused on developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism. Its research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena. The Company's product, Alkindi, is a hydrocortisone specifically designed for use in children suffering from pediatric adrenal insufficiency (AI). Alkindi is an oral, immediate-release pediatric formulation of hydrocortisone granules in capsules for opening that allows for accurate age-appropriate dosing in children. Its pipeline includes Chronocort, DITEST, T3 modified release and Oligonucleotide (siRNA). Chronocort is a modified-release preparation of hydrocortisone that is specifically designed to mimic the circadian rhythm of cortisol.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.